StemCell Therapy

There is one group that by their actions, rather than words, loves a good screening test; the top hospitals for heart and cardiac surgery, our premier academic medical centers. Researchers [1] called administrators at these top hospitals inquiring about their executive wellness programs. For the unacquainted, these executive wellness programs carry out half and one-day evaluations of executives, or the wealthy worried well specifically looking for diseases to be treated, as well as lifestyle, behavior modifications. Since the authors are cardiologists and cardiovascular disease remains the #1 cause of death they focused on the testing provided.

The Results

Of the 12 tests, none of them are recommended by the ACC/AHA (American College of Cardiology/American Heart Association), the USPSTF (United States Preventative Services Task Force, or ACPM (American College of Preventative Medicine) to be applied indiscriminately to asymptomatic adults.

And you can be sure that members of the faculty at all these institutions were involved in setting those standards. There are flaws, freely acknowledge, in the study. Most importantly, the information came from administrators, not the actual clinicians so perhaps these tests were not applied to everyone, without consideration of their symptoms or risk. And while we have the charges, in a world of medical opacity, we dont really know what was paid by insurance or out of pocket. But the researchers' final point is, to my mind, the most important, so I will leave them the last words.

In addition to clinical care, the top cardiology hospitals also provide medical education. Offering executive physicals with tests that are not recommended for healthy persons to anyone who can pay out of pocket potentially sends the message to trainees that a 2-tier health care system is acceptable, and that evidence is not important. Furthermore, indiscriminate screening can create a cascade effect and thus violate the principle of primum non nocere (first do no harm) wherein unnecessary tests may create a chain of events resulting in additional ill-advised tests or treatments that may cause avoidable physical or psychological harm.

[1] Researchers were from Washington University School of Medicine and the St. Louis School of Medicine not part of the top 20, so no conflict of interest although the cynical might cry sour grapes.

Source: Assessment of Cardiovascular Diagnostic Tests and Procedures Offered in Executive Screening Programs at Top-Ranked Cardiology Hospitals JAMA Internal Medicine DOI: 10.1001/jamainternmed.2019.6607

Read the rest here:
A New Form of Health Inequality - American Council on Science and Health

Medical costs will continue to outpace general inflation by close to 3 times with the regional average expected to be 13.6 per cent in 2019, says the Mercer Marsh Benefits (MMB) Key Medical Trends in the Middle East and North Africa report.

This is anticipated to grow to 14 per cent in 2020. As the cost of delivering health benefit programmes continues to rise across the region, employers are working with the likes of Mercer Marsh Benefits to develop smarter healthcare plans and embrace wellness and preventive medicine.

Regionally, the top three health risk factors influencing medical costs are respiratory conditions, diseases of the circulatory system and endocrine and metabolic diseases.

Type 2 diabetes remains a significant concern across the Middle East, with KSA having the highest prevalence of the condition (31.6 per cent) followed by Oman (29 per cent), Kuwait (25.4 per cent), Bahrain (25 per cent), and the UAE (25 per cent).

With several countries in the region looking to introduce mandatory healthcare regimes, employers will need to combat the over utilisation of benefits and the underutilisation of primary care. The commercialization of the hospital sector, together with the increasing availability of healthcare is driving an uptake in healthcare services and the resulting costs.

Employers face a challenge in balancing the cost of healthcare provision with the quality needed to meet regulatory standards and employee needs.

The top three causes for the increasing costs the region faces are; (1) the over prescribing of low-value health tests and procedures, (2) high cost pharmaceuticals and (3) overly lengthy inpatient stays.

Julio Villalon Garcia, Mercer Marsh Benefits Leader, Middle East & Africa, said: Although there are clear challenges facing us, the region is making significant investment into tackling some of the issues raised in this report, specifically by encouraging employees to take greater personal responsibility for their own well-being through more visible support for preventative care. The MEA region is a global leader in adopting virtual health consultancies and telemedicine, and 88 per cent of our respondents are either considering or already support this new technology the global figure is 78 per cent.

In time, I expect employees to develop a better understanding of their own healthcare needs. This, together with improved access to preventive care and simpler and more user-friendly technology, has the potential to allow medical inflation to be better managed. -- Tradearabia News Service

Read this article:
Regional healthcare costs at 3 times the rate of inflation - Trade Arabia

Twin sisters have opened a vet surgery which treats pets with herbal remedies including mistletoe and medicinal mushrooms.

Reagan and Jordan Carnwath, 29, grew up 'obsessed' with animals and in their childhood would bring sick or injured creatures home to care for them.

The identical twins both studied veterinary medicine at the University of Glasgow, and Reagan graduated in 2013 with Jordan completing her studies a year later.

After finishing her studies, Reagan moved to Dumfries and Galloway to work in a rural veterinary surgery, but in 2017 she returned to her home city and established Herbal Vet Scotland.

Unlike most vet surgeries, regular services such as spaying and neutering are not performed at the practice, in Glasgow's South Side.

Instead, complementary holistic treatment is given in addition to regular medical care provided elsewhere, on a referral basis meaning medical records can be accessed.

Pet owners could be issued with recipes for meals to cook for their pets, and acupuncture could be performed as a form of pain relief.

But Reagan says the business is the 'first of its kind' in Scotland, and their patients include cats, dogs, and horses.

She stays at the Glasgow branch while Jordan travels further afield in Scotland to visit patients on their farms.

Reagan said: "We're the only dedicated herbal practice of its kind in Scotland.

"If animals need conventional treatments we'll send them back to their regular vets but we choose to model on holistic medicine and it seems to work well.

"In North America it's really big with vets that work in this way.

"It's important because it shows these treatments are effective.

"A lot of people worry about coming across a vet like us and wonder how effective it is.

"We're not replacing conventional veterinary care.

"We see a lot of animals with skin diseases and cancers.

"We're not saying 'we can cure cancer', but we have a whole lot of treatments we do such as injections of mistletoe and diet changes.

"One of our patients got diagnosed with a rare form of cancer of the adrenal gland and the vet said it would be weeks to months to live.

"We saw the dog and started him on weekly injections of mistletoe and now he's doing really well - he's full of energy and acting like a puppy again.

"We won't say we've cured him, but he's living a really good quality of life.

"He's on medication to control his blood pressure, that's the only conventional medicine he's on.

"He's also on a home cooked diet and medicinal mushrooms as well."

Both sisters believe that raw diets, including raw meat, can be beneficial to animals - but they also provide owners with recipes for home cooked meals.

Reagan, from Cambuslang, Glasgow, said: "We give the owners recipes and they cook them up at home.

"They cook a big batch up and can freeze it so it's not too time consuming.

"An advantage is you know exactly what's going on.

"Dog food can be quite processed with meat derivatives."

Herbal powders, creams and ointments are also prescribed as treatment, along with mistletoe injections.

Reagan said a home cooked diet and herbal treatments can be 'preventative' and keep animals healthier so they don't need as much conventional veterinary care.

She said: "Some conventional medicines like steroids are super cheap but others are really expensive.

"We offer puppy and kitten consultations to get diets right, reducing needs for over vaccination - setting them up to be as healthy for as long as possible.

"It's preventative.

"It's really the future of preventative medicine."

Reagan added: "Since little girls we were obsessed with animals and we've been lucky to grow up and realise our dream to become vets.

"We were animal mad and always bringing injured ones home to our mum, much to her delight."

See original here:
Scots twins open vets to treat pets with herbal remedies including mushrooms and mistletoe - Daily Record

The bathroom scale..friend or foe?

Todays discussion is about our second ingredient for change Monitoring.

Monitoring is exactly what it sounds like, we take a measure as the baseline (the starting point) and then we continue to measure and track the results of our efforts to see if our change plan and the actions we take are having the desired effect.

So, lets look at how were going to use this concept to build our skills for change and talk about the number one tool for positive changes to our health and body composition, the bathroom scale. As a career personal trainer, I coach health and wellness through nutrition and exercise and I understand the sensitivity, the emotion, and the challenges associated with our physique culture, perceptions of body image and our health. And the bathroom scale is not without a little controversy.

The short and sweet answer is a resounding YES, followed with DAILY, possibly even twice daily, upon rising and before bed. Lets look at why it may have been, and continues to be, a little controversial. Ask 10 trainers or give it a quick google and youll find that there are those that think monitoring (see what I did there?) your weight is not a good idea.

It starts with physiology. Our bodies are composed primarily of water, the average human being has a baseline level that fluctuates between 45% and 75%, depending on age, gender and body composition (fat mass vs. lean mass). So, lets assume that a healthy individual has a baseline of 60% water. Now, this baseline level varies with nutrition, activity level, exposure to the sun, wind, etc. and as a woman, it also fluctuates with your menstrual cycle. A 150 lb individual is about 68 kg, which translates into 41 litres of water. A 5% change to that baseline, which happens all the time, can result in + or of approximately 4 lbs!

Its often assumed that weighing yourself might be adverse psychologically, causing depression, promoting body dysmorphia, or at the very least, a negative self-perception. The idea that we might not understand that water levels fluctuate with salt, or alcohol intake, or a womans menstrual cycle, and that seeing the number on the scale jump around a little, could cause some serious psychological issues has been put to the test and found to be false. One study on the effects of daily self-weighing in the American Journal of Preventative Medicine presented the findings of a randomized controlled trial comprised of 91 men and women and it concluded that there were no adverse psychological effects. The researchers recommended daily self-weighing as a primary weight control strategy. It turns out that the scale is not our enemy.

Back to the concept of monitoring. How can you change what you dont track? In several other recent studies participants were required to weigh themselves daily, that was it. Just get on the scale, same time, every day. It turns out that weighing yourself daily resulted in significant and clinical weight loss. They called it adoption of weight control measures simply put, if you track something, you pay attention to what might affect it.

In the field of industrial and organizational psychology its known as the Hawthorne Effect (I had to use that one) it was first recognized in the 1950s in an analysis of earlier studies of productivity done at Western Hawthorne Electric. The initial study results were confusing to researchers. It didnt matter what was being manipulated, production went up. If the lights were dimmed productivity improved, but if they were brightened it also improved! It wasnt until years later researchers realized that it wasnt the specific intervention, but the observation that improved productivity. When someones watching production goes up!

If your goal is to lose bodyfat and improve your body composition, the number on the scale has to down, its that simple. The concept of swapping bodyfat for muscle or losing inches without change on the scale is wrong, the rates of change are just not the same. Muscle growth is challenging, it takes time and effort to build strength and size. Now this is entirely anecdotal, but I competed in drug-tested bodybuilding competitions and over the course of 8 years my stage weight went from 204 lbs to 220 lbs. As a professional trainer with a goal of winning National and International titles I gained an average of 2lbs of muscle per year.

Monitoring is critical to successful change and if youve decided to start weighing yourself daily, just take note that your weight goes up and down for a variety of reasons and that tracking and recording your weight wont result in a nice straight line. The points on that line will fluctuate up and down, but as long as that trend is dropping, youre on target!

Sean Hawthorne is the owner and operator of OneLife Health and Wellness, Kelownas first and longest running private, personal training facility. While working in Dubai, UAE as a Contracts and Project Manager, Sean decided to leave his successful career in Civil Engineering Technology and pursue his passion for health, fitness and helping others achieve their goals. He returned to Canada in 2001, taking formal education in Exercise Science and starting his career in the field of health and fitness. Working in collaboration with their clients, Sean and his team of health and fitness professionals strive to continually improve their skills and to help everyone reach their goals.

Contact Sean:

1-life.ca/

Facebook

bravoformula.com/

Like us on Facebook and follow us on Twitter.

Read more:
HAWTHORNE: Monitoring, the bathroom scale - Pentiction Western News

'); $("#expandable-weather-block .modal-body #mrd-alert"+ alertCount).append(""+val.title+""); // if (window.location.hostname == "www.kmov.com" || window.location.hostname == "www.kctv5.com" || window.location.hostname == "www.azfamily.com" || window.location.hostname == "www.kptv.com" || window.location.hostname == "www.fox5vegas.com" || window.location.hostname == "www.wfsb.com") { if (val.poly != "" && val.polyimg != "") { $("#expandable-weather-block .modal-body #mrd-alert"+ alertCount).append('"+val.ihtml+""); $("#expandable-weather-block .weather-index-alerts").show(); $("#expandable-weather-block .modal-body h2").css({"font-family":"'Fira Sans', sans-serif", "font-weight":"500", "padding-bottom":"10px"}); $("#expandable-weather-block .modal-body p").css({"font-size":"14px", "line-height":"24px"}); $("#expandable-weather-block .modal-body span.wxalertnum").css({"float":"left", "width":"40px", "height":"40px", "color":"#ffffff", "line-height":"40px", "background-color":"#888888", "border-radius":"40px", "text-align":"center", "margin-right":"12px"}); $("#expandable-weather-block .modal-body b").css("font-size", "18px"); $("#expandable-weather-block .modal-body li").css({"font-size":"14px", "line-height":"18px", "margin-bottom":"10px"}); $("#expandable-weather-block .modal-body ul").css({"margin-bottom":"24px"}); $("#expandable-weather-block .modal-body pre").css({"margin-bottom":"24px"}); $("#expandable-weather-block .modal-body img").css({"width":"100%", "margin-bottom":"20px", "borderWidth":"1px", "border-style":"solid", "border-color":"#aaaaaa"}); $("#expandable-weather-block .modal-body #mrd-alert"+ alertCount).css({"borderWidth":"0", "border-bottom-width":"1px", "border-style":"dashed", "border-color":"#aaaaaa", "padding-bottom":"10px", "margin-bottom":"40px"}); }); } function parseAlertJSON(json) { console.log(json); alertCount = 0; if (Object.keys(json.alerts).length > 0) { $("#mrd-wx-alerts .modal-body ").empty(); } $.each(json.alerts, function(key, val) { alertCount++; $("#mrd-wx-alerts .alert_count").text(alertCount); $("#mrd-wx-alerts .modal-body ").append(''); $("#mrd-wx-alerts .modal-body #mrd-alert"+ alertCount).append(""+val.title+""); // if (window.location.hostname == "www.kmov.com" || window.location.hostname == "www.kctv5.com" || window.location.hostname == "www.azfamily.com" || window.location.hostname == "www.kptv.com" || window.location.hostname == "www.fox5vegas.com" || window.location.hostname == "www.wfsb.com") { if (val.poly != "" && val.polyimg != "") { $("#mrd-wx-alerts .modal-body #mrd-alert"+ alertCount).append(''); } else if (val.fips != "" && val.fipsimg != "") { // $("#mrd-wx-alerts .modal-body #mrd-alert"+ alertCount).append(''); } // } //val.instr = val.instr.replace(/[W_]+/g," "); $("#mrd-wx-alerts .modal-body #mrd-alert"+ alertCount).append(val.dhtml+"

Instruction

Link:
Power of regenerative medicine - KCTV Kansas City

Cape Cod, MA- Leadership Cape Cod is excited announce the launch of the 28th annual Community Leadership Institute and the class of 2020. Between January and May, 26 professionals and developing leaders will attend 11 sessions across Cape Cod meeting and learning from prominent community leaders in business, healthcare, the arts, education, social services and more. While participating in the course participants will also work together to develop and engage in community service projects benefiting local non-profit organizations on Cape Cod.

The Community Leadership Institute (CLI) is the foremost program offered by Leadership Cape Cod and has run since 1992. CLI has fostered the growth of existing and potential community leaders on Cape Cod and graduated more than 700 people who have learned about leadership from prominent community leaders. This rigorous and diverse program is presented annually from January to June immerses participants in all areas of the Cape Cod community and professional fields, including: healthcare, social services, education, business, government, law, environment, media and the arts. Participants learn about current and developing issues facing Cape Cod and the Islands, how to become more involved in providing the leadership needed to help address these challenges.

Class members complete a community service project to benefit a local non-profit and a commencement ceremony is held in June. Through this course and community service participants gain access to individuals working to solve the Capes most pressing issues. Students are encouraged to think about their role in creating solutions to local and regional challenges. CLI alumni include local and state politicians, business and nonprofit leaders, entrepreneurs, educators, health care professionals and members of the media.

Leadership Cape Cods Community Leadership Institute (CLI) class of 2020 is comprised of: Rochelle Ricki Ackell (Cape Abilities), Kayla Baier (AmeriCorps Cape Cod), Jamie Brids (My Generation Energy), Courtney Butler (Town of Wellfleet), Andrew Coleman (YMCA of Cape Cod), Kim Devine (Cape Cod 5), Stephen Dignam (The Cooperative Bank of Cape Cod), Kathryn Eident (WCAI-FM), Nivia Fagundes (Integrative Medicine Holistic Wellness Center), Richard Falzone, Christine Hochkeppel (Salty Broad Studios), Tamora Israel (The Cordial Eye Gallery and Artist Space), Stephen Katzenback (Spaulding Rehabilitation Hospital), Emily Kelly-Joseph (Cape Wellness Collaborative), Anne Mayo, Tarraza Millard (Cape & Islands Workforce Board), Margeaux Prendergast Weber (Cotuit Center for the Arts), James Quitadamo (The Cooperative Bank of Cape Cod), Pamela Sears (The Cooperative Bank of Cape Cod), Lisa Simundson (Orleans Chamber of Commerce), Jeffrey Skeiber (Spaulding Rehabilitation Hospital), Blane Toedt (The West End), Emily Tullock (Cape Media News), Tara Wallace, Danielle Wilson (May Institute), Steven Xiarhos (Yarmouth Police Department).

The first session of the 2020 class took place on January 9th at Joint Base Cape Cod with presentations from Colonel Virginia I. Gaglio Chief of Staff and Air Component Commander, Massachusetts Air National Guard and Assistant Adjutant General (Air) for the Commonwealth of Massachusetts, State Military Division, Judy Walden Scarafile - Managing Director of the Major Crisis Relief Fund, Matthew Burke Co-President of Cape Cod 5.

See the original post here:
Leadership Cape Cod Announces CLI Class of 2020 - Cape Cod Today

Common myths about low back pain could lead to more pain, ineffective care and unwarranted anxiety, researchers say.

Low back pain is the worlds leading cause of disability, and its often associated with costly care that can sometimes be harmful, Peter OSullivan and colleagues write in an editorial in the British Journal of Sports Medicine.

Myths about back pain are common and can be reinforced by the media and well-meaning clinicians, the authors note.

This misinformation can lead people to fear back pain, respond to it in unhelpful ways and drive poor health care, OSullivan said in an email. Myths often cause negative emotional responses such as fear, distress and loss of hope, he added, as well as behaviors like over-protecting the back and avoiding movement, activity and work.

OSullivan, a specialist physiotherapist with the School of Physiotherapy and Exercise Science at Curtin University in Perth, Australia, told Reuters Health that almost daily he comes across patients who hold unhelpful beliefs.

In their editorial, OSullivan and his colleagues identify 10 common myths about low back pain and counter each of them with back pain facts that are supported by evidence.

Among the myths are the idea that low back pain will become persistent and will worsen with age, that pain is always a sign of tissue damage and requires rest, and that scans and invasive procedures are always needed to diagnose and treat low back pain.

In fact, the authors write, the evidence says that persistent back pain can be scary, but its rarely dangerous or life-threatening and its unlikely to leave you in a wheelchair.

Getting older is not a cause of back pain, they add, and evidence-based treatments can help at any age. Persistent low back pain is rarely related to tissue damage and scans rarely show the cause of back pain.

Low back pain is not caused by poor posture while sitting, standing and bending, and its also not caused by weak core muscles. Injections, surgery and strong drugs usually arent effective for persistent back pain in the long term. Finding low-risk ways to control pain is key.

Dr. Houman Danesh, director of Integrative Pain Management at the Icahn School of Medicine at Mount Sinai in New York City, said its common in his experience, too, to find patients holding beliefs like those in the list of myths.

I usually have to spend a portion of my office visit untangling them, the most common being patients who say they have a herniated disc from 20 years ago and have chronic back pain. That is a rare occurrence, Danesh, who was not involved in the editorial, told Reuters Health in an email.

It is sad and frustrating when patients take on a false identity based on a myth and lose a large part of their quality of life.

Danesh disagreed, however, with some of the authors advice. For instance, there are cases when strong medications, injections or surgery can be used to treat low back pain, so that is not entirely a myth, he said.

There are times these treatments are necessary, and a medical evaluation is needed to determine the best course of treatment.

OSullivan said research into understanding back pain has increased, but societal beliefs and clinical practice were slow to catch up.

Clinicians and doctors must spend time to ask patients what they understand about their back pain its cause, consequences and how best to care for it and then provide practical ways to manage it, he said.

Read more here:
Researchers: Myths may worsen low back pain and promote ineffective treatments - The Union Leader

When Breighl Robbins gave birth to her daughter nearly three years ago, she experienced what many new moms come up against: My awareness and attention was completely on Phyllis to such an extreme that I wasnt taking care of myself anymore, recalls the 30-year-old, who realized that while she was fortunate enough to have help with her baby, she herself suddenly felt ill-equipped to handle the emotional and physical challenges of the postpartum period. What was missing was someone communicating to me or giving me the tools that I needed to take care of myself well. Now, after consulting with doctors and doulas alike, Robbins, who began her career in public health and integrative medicine, has set out to fill that void with the launch of Ebi (family in Yoruba), a line of wellness essentials made with the fourth trimester in mind.

Self-care is a vital piece of having a healthy and holistic postpartum experience, Robbins explains, gesturing toward her trio of plant-based products, which are formulated with balancing botanical ingredients safe enough for your mini-me. Bottled by hand in her Boston studio, an oil blend of sunflower, sesame seed, and almond can be used for C-section scars, itchy nipples, and diaper rash or, simply, a much-needed massage, while the nutritive oat tops found in the tisane support healthy milk production and energy levels. Consider too Ebis take on the traditional sitz bath, which can help heal perineal tissue post-pregnancythough anyone is sure to delight in its relaxing herbal blend and amber-hued glass packaging: It looks very good in your bathroom, Robbins, wearing a ruffled Batsheva frock, says with a laugh.

Robbins is taking Ebi beyond the vanity as well, thanks to organic cotton nursing pads and underwear, complete with an invisible leak-proof liner and a compression band thats made from Repreve, an eco-friendly fabric containing recycled materials; this spring, she will also partner with Domino Kirkes Carriage House Birth as well as Doula Trainings International to better equip mothers-to-be: Youre stepping into this new role, she muses. Its not the body you once knew; youre not the person you once knew. I think taking the time to pause and acknowledge that is something a lot more women are starting to become aware of.

Visit link:
Meet Ebi, the Brand Bringing Self-Care to the Postpartum Experience - Vogue

Gary from Carmel writes, You have helped me out in the past so thought Id get your opinion on this. On a recent show, a doctor was talking about which foods to eat and which to avoid. He said that you should be eating nuts, but dont eat cashews, as they are not a nut, but rather a seed, and contain high levels of lectin. I always thought that cashews were a tree nut just like walnuts, etc. Can you shed some light on this for me?

Dear Gary,

In this case, Im afraid my opinion would not be worth much. I needed the expertise of horticulturist, Pat Regan, who humbly describes himself as a friend who spends a lot of time pondering plant parts and identification.

Pat explains that the names we commonly use often distort the scientific terms for plant parts. Fruit and vegetable are typically considered the worst abused but nut probably comes in first place, he says.

All true nuts are seeds, but not all seeds are nuts, says Pat.

Kind of like all trees are plants but not all plants are trees?

Absolutely.

So a nut is a type of seed. Got it.

Botanically, he continues, a nut is a dry fruit with one seed and a thick hard shell. Think of acorns, hazelnuts, chestnuts or hickory nuts. On the other hand, cashews come from a fleshy fruit, not a hard shell. They are more like plums, apricots, cherries and olives.

Cashews, says the Integrative Medicine Department at UC Davis, are technically not a nut. Although they grow on trees, they are really seeds that grow from a strange-looking fruit called a cashew apple.

Incidentally, Pat continues, peanuts (a legume), walnuts, almonds and pecans are not true (botanical) nuts, either. Nor are pine nuts, pistachio nuts and Brazil nuts, and yet most would call me a nut for saying so.

As for lectins, these are proteins that occur naturally in most raw plants, including cashews. The good news is that cooking destroys the activity of these proteins one reason why cashews are always sold roasted or steamed.

The other reason is that raw cashews are enclosed in a shell that contains a resin called urushiol, the same rash-causing substance found in poison ivy. Heat inactivates urushiol another reason cashews are always sold shelled and roasted or steamed.

One last word about nuts in general, including the not true nuts. They are a good source of protein, micronutrients, healthful fats and disease-fighting antioxidants. And according to the Micronutrient Information Center at Oregon State University, consuming a variety of nuts on a regular basis is associated with a lower risk for heart disease and Type 2 diabetes.

To which Pat adds, It does not sound like eating cashew seeds is such a bad idea. Thank you, friend.

Barbara Quinn is a registered dietitian nutritionist affiliated with the Community Hospital of the Monterey Peninsula.

Read the rest here:
Nutrition: A look at nuts that are not nuts - Duluth News Tribune

Chien-Shan Cheng, 1, 2,* Jing-Xian Chen, 3, 4,* Jian Tang, 1, 2 Ya-Wen Geng, 1, 2 Lan Zheng, 3, 4 Ling-Ling Lv, 3 Lian-Yu Chen, 1, 2 Zhen Chen 1, 2

1Department of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, Peoples Republic of China; 2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, Peoples Republic of China; 3Department of Traditional Chinese Medicine, Ruijin Hospital, Jiaotong University School of Medicine, Shanghai 200025, Peoples Republic of China; 4Workstation of Xia Xiang, National Master of Traditional Chinese Medicine, Department of Traditional Chinese Medicine, Ruijin Hospital, Jiaotong University School of Medicine, Shanghai 200025, Peoples Republic of China

*These authors contributed equally to this work

Correspondence: Zhen Chen; Lian-Yu ChenDepartment of Integrated Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, Peoples Republic of ChinaTel +86-21-6417-5590 ext. 83628Email cz120@mail.sh.cn; lianyu_chen@hotmail.com

Purpose: Paeonol, a natural product derived from the root of Cynanchum paniculatum (Bunge) K. Schum and the root of Paeonia suffruticosa Andr. (Ranunculaceae) has attracted extensive attention for its anti-cancer proliferation effect in recent years. The present study examined the role of paeonol in suppressing migration and invasion in pancreatic cancer cells by inhibiting TGF- 1/Smad signaling.Methods: Cell viability was evaluated by MTT and colonial formation assay. Migration and invasion capabilities were examined by cell scratch-wound healing assay and the Boyden chamber invasion assay. Western Blot and qRT-PCR were used to measure the protein and RNA levels of vimentin, E-cadherin, N-cadherin, and TGF- 1/Smad signaling.Results: At non-cytotoxic dose, 100 &Mgr; and 150 &Mgr; of paeonol showed significant anti-migration and anti-invasion effects on Panc-1 and Capan-1 cells (p< 0.01). Paeonol inhibited epithelial-mesenchymal-transition by upregulating E-cadherin, and down regulating N-cadherin and vimentin expressions. Paeonol inhibited TGF- 1/Smad signaling pathway by downregulating TGF- 1, p-Smad2/Smad2 and p-Smad3/Smad3 expressions. Further, TGF- 1 attenuated the anti-migration and anti-invasion capacities of paeonol in Panc-1 and Capan-1 cells.Conclusion: These findings revealed that paeonol could suppress proliferation and inhibit migration and invasion in Panc-1 and Capan-1 cells by inhibiting the TGF- 1/Smad pathway and might be a promising novel anti-pancreatic cancer drug.

Keywords: paeonol, pancreatic adenocarcinoma, TGF- 1/Smad signaling, epithelial-mesenchymal-transition, Cynanchum paniculatum

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

See the article here:
Paeonol Inhibits Pancreatic Cancer Cell Migration and Invasion Through | CMAR - Dove Medical Press

Guava benefits: One guava offers 200% of daily recommended intake of Vitamin C

Guava benefits: Guava, as nutritionist Rujuta Diwekar mentions, is a local fruit which is in season right now. Guava or amrud is a Vitamin C-rich fruit with lots of antioxidants, potassium and fibre. Eating guava every day can be beneficial for your blood sugar levels, heart health, digestive system and also weight loss. Lifestyle coach Luke Coutinho recently took to Instagram to talk about guava, mentioning how the fruit is great for boosting immunity and energy levels. So let's see why all health experts are talking about this seasonal fruit.

One of the most essential nutrients that guava contains is Vitamin C. It is the one nutrient that can boost your immunity enough to keep you healthy and disease-free. Nutritionist Nmami Agarwal says that one guava offers 200% of daily recommended intake of Vitamin C.

"Vitamin C is a powerful antioxidant that prevents from free radical damage and keeps the skin supple and glowing. It also contains lycopene, powerful antioxidant which has been scientifically proven protect against certain types of cancer," Nmami tells DoctorNDTV.

Vitamin C-rich guava can boost your immunity and help you be disease-freePhoto Credit: iStock

Also read:Nutritionist Recommended Foods For Quicker Healing, Stronger Immunity And Improved Overall Health

Guavas are naturally low in glycemic index. Thismakes them a perfect choice for diabetics, Nmami adds. "Guavas are also rich in fibre. Including them in your diet can improve digestive health and keep constipation at a bay," she says.

The best part about guava is that its not just the fruit which provides with health benefits, its leaves are equally beneficial. Nmami informs that guavas contain antibacterial and anti-inflammatory properties. "Guava leaves are also a perfect antidote for diarrhoea," she informs.

Also read:Inflammation: What Are The Risks Of High Inflammation In The Body?

As mentioned above, you can have guava as a mid-meal snack. You can eat the whole fruit without peeling the skin. "You can add guava to a smoothie or combine guava slices with cottage cheese cubes," recommends Nmami.

You can prepare guava chutney with guava leavesPhoto Credit: iStock

For consuming guava leaves, you can brew them in a tea or blend them to form a guava chutney.

This season, enjoy guavas without guilt. Make sure you eat at least one every day!

Also read:Turmeric Tea: Amazing Health Benefits You Cannot Afford To Miss; Learn How To Make Turmeric Tea

(Nmami Agarwal is nutritionist at Nmami Life)

(Rujuta Diwekar is a nutritionist based in Mumbai)

(Luke Coutinho, Holistic Lifestyle Coach - Integrative Medicine)

Disclaimer: This content including advice provides generic information only. It is in no way a substitute for qualified medical opinion. Always consult a specialist or your own doctor for more information. NDTV does not claim responsibility for this information.

Read the original post:
Guava Health Benefits: Here's Why Health Experts Are Talking About Vitamin C-Rich Amrud - NDTV News

Four members of the University of Colorado Boulder facultyhave been named 2019Professors of Distinction by the College of Arts and Sciences in recognition of their exceptional service, teaching and research.

The new professors of distinction areNoel Clarkof physics,Stephen Graham Jonesof English,Robert Pasnauof philosophy, andKenneth P. Wright Jr.of integrative physiology.

This reveredtitleis reserved for scholars and artists of national and international acclaim whose college peers also recognize as exceptionally talented teachers and colleagues. Honorees of this award hold this title for the remainder of their careers in the College of Arts and Sciences at CU Boulder.

The four will be honored onMonday, Feb. 3,at 3:30 p.m. in the CASE Auditorium/Chancellors Hall. At the free and public event, Clark, Jones and Wright will give a public presentation based on his research or scholarly work. Pasnau is unable to attend the event this year but will give his presentation next year.

Wright, Pasnau, Clark, and Jones. (left to right).

Noel Clark, whose talk is titledSplashing Around in Soft Matter,received his PhD in Physics from MIT in 1970. He subsequently held the positions of research fellow and assistant professor of applied physics at Harvard, before moving to CU Boulder in 1977.

Research in Clark's group is directed toward understanding and using the properties of condensed phases, ranging from experiments on the fundamental physics of phase transitions, such as melting, to the development of liquid crystal electro-optic light valves.

His primary experimental tools are laser light scattering, electrooptics, video microscopy and high resolution synchrotron X-ray scattering. Much of the research is on the physics of liquid crystals, phases of matter having structure intermediate to that of liquids and solids, and on the physics of colloids, suspensions of one material in another that exhibit order on large length scales.

Stephen Graham Jones, whose Feb. 3 talk is titledBeing Indian is Not a Superpower,is the Ivena Baldwin Professor of English. He received his PhD in Creative Writing (Fiction) from Florida State University in 1998, and came to CU in 2008. At that time, he had five novels and one story collection published.

Since then he's published 11 more novels, five more story collections, and some novellas and comic books and chap books, and he's currently got north of 300 stories published. He has been an NEA recipient, has won the Texas Institute of Letters Award for Fiction, the Independent Publishers Award for Multicultural Fiction, a Bram Stoker Award, four This is Horror Awards, and hes been a finalist for the Shirley Jackson Award, the World Fantasy Award, the Wonderland Book Award, and the Colorado Book Award.

Hes also made Bloody Disgustings Top Ten Horror Novels, and will soon receive the Western Literature Association's Distinguished Achievement Award. At CU Boulder he's won the Carolyn Woodward Pope Prize for Faculty Publication, the Boulder Faculty Assembly Excellence in Research Award, and the Kayden Book Award, and he's a faculty affiliate with the Center for Native American and Indigenous Studies, the Center for the American West, and the Department of Ethnic Studies.

Aside from teaching fiction and screenwriting workshops, Jones teaches courses on comic books, the haunted house, the slasher, the zombie and the werewolf. His fiction navigates the spaces between the commercial and the literary, often using the tropes of horror and fantasy and science fiction and the western and noir in unconventional ways. He says he's not running out of stories anytime soon, either.

Kenneth P. Wright Jr., whose talk is titledSleep for Optimal Health and Performance,is a professor in the Department of Integrative Physiology and the director of the Sleep and Chronobiology Laboratory at CU-Boulder.

Wright received a BS in psychology from the University of Arizona (1990) and a PhD in Behavioral Neuroscience from Bowling Green State University (1996). Following postdoctoral training in the Division of Sleep Medicine at Harvard Medical School and Brigham and Womens Hospital, he served on the faculty at Harvard Medical School prior to joining the faculty at CU Boulder in 2002.

Wright has more than 25 years of experience in sleep and circadian research, has led individual and multicenter/transdisciplinary team projects, and has participated in multicenter clinical trials. His research aims to understand the physiology of sleep and circadian rhythms in humans and the health and safety consequences of sleep and circadian disruptionsuch as, metabolic dysregulation, impaired cognition, and compromised performance.

Wrights research also explores strategies to promote sleep, enhance alertness and maintain health and safety when sleep and circadian rhythms are challenged, as well as treatment strategies for patients with sleep and circadian related disorders.

He is a frequently invited speaker and media contact and has published more than 115 peer-reviewed articles. Wright manages a large undergraduate, graduate and postgraduate training program in sleep and circadian physiology at CU Boulder.

Wright has served in leadership, consulting, and advisory roles for government, professional, community, and commercial stakeholders, such as, the Sleep Disorders Research Advisory Board of the National Institutes of Health, National Heart, Lung, and Blood Institute, and the Board of Directors of the Sleep Research Society. He also serves as a reviewer for numerous national and international granting agencies and scientific journals.

Robert Pasnauhas taught in the Department of Philosophy since 1999. His research concentrates on the history of philosophy, particularly the end of the Middle Ages and the beginnings of the modern era.

He is the editor of theCambridge History of Medieval Philosophyand ofOxford Studies in Medieval Philosophy. His most recent book,After Certainty: A History of Our Epistemic Ideals and Illusions(OUP 2017), is based on his Isaiah Berlin Lectures, delivered at Oxford University in 2014.

Pasnau is the founding director of the Benson Center for the Study of Western Civilization.

See original here:
Newly minted professors of distinction to be celebrated - CU Boulder Today

Nanotechnology is one of the most promising technologies in 21st century. Nanotechnology is a term used when technological developments occur at 0.1 to 100 nm scale. Nano medicine is a branch of nanotechnology which involves medicine development at molecular scale for diagnosis, prevention, treatment of diseases and even regeneration of tissues and organs.

Thus it helps to preserve and improve human health. Nanomedicine offers an impressive solution for various life threatening diseases such as cancer, Parkinson, Alzheimer, diabetes, orthopedic problems, diseases related to blood, lungs, neurological, and cardiovascular system.

Development of a new nenomedicine takes several years which are based on various technologies such as dendrimers, micelles, nanocrystals, fullerenes, virosome nanoparticles, nanopores, liposomes, nanorods, nanoemulsions, quantum dots, and nanorobots.

In the field of diagnosis, nanotechnology based methods are more precise, reliable and require minimum amount of biological sample which avoid considerable reduction in consumption of reagents and disposables.

Get Sample Copy of Report @https://www.persistencemarketresearch.com/samples/6370

Apart from diagnosis, nanotechnology is more widely used in drug delivery purpose due to nanoscale particles with larger surface to volume ratio than micro and macro size particle responsible for higher drug loading. Nano size products allow to enter into body cavities for diagnosis or treatment with minimum invasiveness and increased bioavailability. This will not only improve the efficacy of treatment and diagnosis, but also reduces the side effects of drugs in case of targeted therapy.

Globalnanomedicinemarket is majorly segmented on the basis of applications in medicines, targeted disease and geography. Applications segment includes drug delivery (carrier), drugs, biomaterials, active implant, in-vitro diagnostic, and in-vivo imaging. Global nanomedicine divided on the basis of targeted diseases or disorders in following segment: neurology, cardiovascular, oncology, anti-inflammatory, anti-infective and others.

Geographically, nanomedicine market is classified into North America, Europe, Asia Pacific, Latin America, and MEA. Considering nanomedicine market by application, drug delivery contribute higher followed by in-vitro diagnostics. Global nanomedicine market was dominated by oncology segment in 2012 due to ability of nanomedicine to cross body barriers and targeted to tumors specifically however cardiovascular nanomedicine market is fastest growing segment. Geographically, North America dominated the market in 2013 and is expected to maintain its position in the near future.

Request Customization of this Report @https://www.persistencemarketresearch.com/request-customization/6370

Asia Pacific market is anticipated to grow at faster rate due to rapid increase in geriatric population and rising awareness regarding health care. Europe is expected to grow at faster rate than North America due to extensive product pipeline portfolio and constantly improving regulatory framework.

Major drivers for nanomedicine market include improved regulatory framework, increasing technological know-how and research funding, rising government support and continuous increase in the prevalence of chronic diseases such as obesity, diabetes, cancer, kidney disorder, and orthopedic diseases. Some other driving factors include rising number of geriatric population, awareness of nanomedicine application and presence of high unmet medical needs. Growing demand of nanomedicines from the end users is expected to drive the market in the forecast period.

However, market entry of new companies is expected to bridge the gap between supply and demand of nanomedicines. Above mentioned drivers currently outweigh the risk associated with nanomedicines such as toxicity and high cost. At present, cancer is one of the major targeted areas in which nanomedicines have made contribution. Doxil, Depocyt, Abraxane, Oncospar, and Neulasta are some of the examples of pharmaceuticals formulated using nanotechnology.

For In-depth Competitive Analysis, Pre-Book Report Now @https://www.persistencemarketresearch.com/checkout/6370

Market Players

Key players in the global nanomedicine market include:

Original post:
Healthcare Nanotechnology Nanomedicine Market : Outlook Continues to Remain Positive by 2015 2021 - The Trusted Chronicle

According to the Shanghai East Hospital of Tongji University, a Messenger RNA (mRNA) vaccine targeting the novel coronavirus (2019-nCoV) may become available in a few months.

The project has already completed an emergency filing.

Announced in a press release on January 28, 2020, the mRNA vaccine will be co-developed by the Shanghai East Hospital and Stermirna Therapeutics Co., Ltd.

Li Hangwen, the CEO of Stermirna Therapeutics, is reported by Xinhua to have said no more than 40 days will be needed to manufacture the vaccine samples based on the new generation of mRNA technology and some preliminary procedures.

Li Hangwen said this accelerated development process can be achieved since mRNA vaccines have shorter development and production cycles.

Separately, Li Hangwen, a project leader of the translational medicine platform of Dongfang Hospital and chairman of Sri Lanka Microbiology, said in a press release that using relevant platform technology, rapid synthesis of mRNAs with different antigen sequences targeting key targets of this new type of coronavirus, and through nano-lipid.

The translational medical platform of Dongfang Hospital affiliated to Tongji University cooperated with Siwei (Shanghai) Biotechnology Co., Ltd. and relied on the subject of "Shanghai Zhangjiang National Independent Innovation Demonstration Zone Stem Cell Strategic Library and Stem Cell Technology Clinical Translation Platform" Sub-task-the results of the mRNA synthesis platform, to quickly promote the development of new coronavirus mRNA vaccines.

This drug-loaded technology is used to prepare the preparation, and in vivo and animal experiments are used to screen and verify effective antigens.

The new generation of mRNA vaccine technology that has emerged in recent years has the advantages of short development and production cycles and can realize the timely production and application of vaccines.

Based on this, large-scale preventive 2019-nCoV vaccine sample production and preparation will be completed within 40 days.

After completing the necessary approval process, the mRNA vaccine candidate can be promoted to the clinic as soon as possible.

Preventive vaccines are the key to extinguishing the large-scale epidemic of major infectious diseases.

In view of the current epidemic of 2019-nCoV, the traditional vaccine has a problem that the production cycle is too long, said this press release. For example, the production cycle of the recombinant protein vaccine takes 5 to 6 months, which cannot meet the need to extinguish the epidemic in time.

Although several vaccine candidates are currently in clinical trials, many still remain in the pre-clinical stage.

Novel coronavirus vaccine news published by Precision Vaccinations.

Read more:
Shanghai Hospital to Develop mRNA Vaccine Targeting the 2019-nCoV in 40 Days - PrecisionVaccinations

Global Antisense and RNAi Therapeutics Market was valued US$ X1.2X Bn in 2019 and is expected to reach US$ XX Bn by 2027, at CAGR of X7.XX% during forecast period of 2020 to 2027.

Global Antisense & RNAi Therapeutics Market

Global Antisense and RNAi Therapeutics Market: Overview

In past years, pharmaceutical companies were motivated about the prospective of RNA interference (RNAi). But later, financial volatility and subsequent suspensions by pharmaceutical companies have articulated that RNAi therapeutics market was fiished. Yet, advances in nano medicine helped the vast potential of RNAi therapeutics to flourish. Antisense technology offers the prospect to influence the gene expression and this is being considered as an effective treatment for various diseases. Based on this factor, great number of gene silencing drugs are in the development process.

The global antisense and RNAi therapeutics market have gathered substantial attention in the recent years, due to its perspective to treat many sort of chronic diseases such as tuberculosis, diabetes, cancer, AIDS, as well as certain cardiovascular problems. This prospect is being cashed on by the many companies in this industry and are investing in R&D. Just to emerge as being in the clinical research division, the RNA based therapeutics are likely to be explored as a most efficient treatment choice for the disorders, which are very difficult to treat. Market is expected to grow at CAGR XX.XX% over the forecast period, as number of companies are into the development of molecules focused on antisense technology.

REQUEST FOR FREE SAMPLE REPORT: https://www.maximizemarketresearch.com/request-sample/46233/

However, there are many challenges associated with the emerging antisense technology and RNAi. One of the noticeable issue is the drug delivery to the proposed portion. Drug delivery to the nervous tissues is one of the problems as the drug has to pass the blood-brain barrier. Major players in the industry are coming up with solutions to overcome these challenges.

The other challenge is toxic effects caused by the use of this technology. Determining the right dosage and path for drug delivery of an antisense molecule is one of the most crucial process to ensure the safe administration. While overcoming this as much as possible and implementing it, companies have encountered multiple rejections from the regulatory bodies. For instance, FDA has refused, an antisense molecule to treat familial chylomicronemia syndrome by the renowned U.S. organization Akceas Waylivra. Such events would push companies to develop better paths, efficient delivery solutions, and effective compositions.

Global Antisense and RNAi Therapeutics Market: Growth Factors

In RNAi therapeutics, more influential product focus vs. platform technologies and virtual drug expansion models that enable several companies to minimize the R&D costs, are expected to attract investors and supplement in the growth of the market. Instead, major issues in drug delivery as well as high failure rates are some of the biggest barriers for companies working in this particular field. Despite the limitations, the players in the pharmaceutical sector are interested and focused for the commercialization of these therapies, hence antisense and RNAi therapeutics market have chances to grow substantially with CAGR of XX.XX% and expected to reach US$ XX.XX Mn by the end of the forecast period.

Global Antisense and RNAi Therapeutics Market: Regional Analysis

North America has experienced to be the most lucrative market in the recent times and has contributed a substantial share in the Global Antisense and RNAi Therapeutics Market. Multiple clinical trials have shown favorable results and are even progressing through the development stages. Supposing such trials expected to show positive results, the North American market can be expected to witness the exponential growth during forecast period. Furthermore in the U.S. several biotechnology companies have made considerably high investments for RNAi therapeutic development and number of RNAi therapeutics are in final stage of development phases. In North America, clinical laboratories are likely to contribute significant revenue generation via platform and product licensing. Supportive government regulation and provision to increase the number of clinical trials therein encourages the method of initiation for exploring antisense therapeutics. The forthcoming commercialization of several players are under R&D will help to boost the global antisense and RNAi therapeutics market in North America in the forecast period.

The increasing government expenditure toward R&D, as well as different forms of siRNA delivery methods, is a strong side propelling the growth of the global antisense and RNAi therapeutics market in Asia Pacific region. Still this region is experiencing the moderate growth rate with CAGR of XX.XX% during 2014-2018, but post commercialization of these therapies, prospects, and forthcoming opportunities in the Asia Pacific are likely to be more profitable, presenting a maximum development rate with the consistently growing CAGR of XX.XX% in the forecast period from 2020 to 2027.

Antisense & RNAi Therapeutics Market Insights and developments

In the recent years there are many discoveries in the field of technologies with regards to Global Antisense & RNAi Therapeutics Market, which in turn will help the industry to grow. Big pharmaceutical developers have entered into collaboration agreements or outsourcing deals with a several of smaller firms & new entrants in an effort to take advantage of on the expected growth in revenue that this market can generate over the forecast period. For instance, Agreement between AstraZenecas and Ionis pharmaceuticals is one of the big deals that are hugely investing & doing R&D into antisense technology.

Since the discovery of RNAi in, there are various ways of treatment of multiple diseases using RNAi, still, the market has picked up very little over the past decade due to the complexities in delivery methodologies associated to RNAi. But due to initiatives by key players and ongoing R&D have shown the chances of better growth.

Rising need for the cure and prevention of diseases like cancer, AIDS and several diseases caused by mutating viruses is anticipated to impact the usage rate of oligonucleotide products. This field is rapidly expanding owing to the increasing number of clinical trials for the oligonucleotide drugs. For instance, Ionis Pharmaceuticals has 2 approved molecules in the European Union and 1 in U.S. along with 4 molecules in pipeline.

Many key players are putting efforts in developing novel delivery systems like nanocarriers, to encourage the in-vivo delivery of the oligonucleotides. To develop the bioavailability, carrying capability of siRNA payload and they deliver high interface with the target cells are the key functions of Nanocarriers, for which they are recognized mostly. The development of newer nanotechnology-oriented methods has offered high potential to the market to grow during the forecast period. Nanocarriers can reduce the toxicity of these oligonucleotides. There is huge need for the latest and harmless delivery systems for cancer and other viral diseases, which is expected to suppliment the market growth. Significant pipeline for cancer therapies by organizations and institutes such as, Enzon Pharmaceuticals (Santaris Pharma), OncoGenex, University of Texas, Astrazeneca (Ionis Pharmaceuticals), Isarna Therapeutics and INSYS Therapeutics, Inc. have huge contribution in driving the market.

Detailed analysis of competition, new entrants, strategic alliances, mergers and acquisition in the Global Antisense & RNAi Therapeutics Market is covered in the report. The report covers the market leaders and followers in the industry with the market dynamics by region. It will also help to understand the position of each player in the market by region, by segment.

DO INQUIRY BEFORE PURCHASING REPORT HERE: https://www.maximizemarketresearch.com/inquiry-before-buying/46233/

Global Antisense & RNAi Therapeutics Market Company Profiles

The players operating in the Global Antisense & RNAi Therapeutics Market, analyzed in the report are:

GSK, Sanofi-Genzyme, Alnylam Pharmaceuticals, Marina Biosciences, Benitec Biopharma, Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Akcea Therapeutics, Quark Pharmaceuticals, Gene Signal

Global Antisense and RNAi Therapeutics Market: Segmentation

The global antisense and RNAi therapeutics market is classified into technology, application, and route of administration. In terms of technology, the global antisense and RNAi therapeutics market is bifurcated into RNA interference and antisense RNA. The segment RNA interference is further sub-divided into miRNA and siRNA. In terms of application, the global antisense and RNAi therapeutics market are categorized into cardiovascular, oncology, renal diseases, respiratory disorder, genetic disorders, a neurodegenerative disorder, infectious diseases, and others. In terms of route of administration, the global antisense and RNAi therapeutics market is sub segmented into intravenous injections, pulmonary delivery, intraperitoneal injections, intradermal Injections, topical delivery, and other delivery methods.Global Antisense and RNAi Therapeutics Market by Technology

RNA Interferenceo siRNAo miRNA Antisense RNAGlobal Antisense and RNAi Therapeutics Market by Application

Oncology Cardiovascular Diseases (CVDs) Respiratory Disorders Renal Diseases Neurodegenerative Disorders Genetic Disorders Infectious Diseases OtherGlobal Antisense and RNAi Therapeutics Market by Route of Administration

Pulmonary Delivery Intravenous Injections Intra-dermal Injections Intraperitoneal Injections Topical Delivery Other Delivery Methods

MAJOR TOC OF THE REPORT

Chapter One: Antisense & RNAi Therapeutics Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Antisense & RNAi Therapeutics Market Competition, by Players

Chapter Four: Global Antisense & RNAi Therapeutics Market Size by Regions

Chapter Five: North America Antisense & RNAi Therapeutics Revenue by Countries

Chapter Six: Europe Antisense & RNAi Therapeutics Revenue by Countries

Chapter Seven: Asia-Pacific Antisense & RNAi Therapeutics Revenue by Countries

Chapter Eight: South America Antisense & RNAi Therapeutics Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Antisense & RNAi Therapeutics by Countries

Chapter Ten: Global Antisense & RNAi Therapeutics Market Segment by Type

Chapter Eleven: Global Antisense & RNAi Therapeutics Market Segment by Application

Chapter Twelve: Global Antisense & RNAi Therapeutics Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Antisense & RNAi Therapeutics Market Report at: https://www.maximizemarketresearch.com/market-report/global-antisense-rnai-therapeutics-market/46233/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website: http://www.maximizemarketresearch.com

Link:
Antisense & RNAi Therapeutics Market By Technology, Route of Administration, Application and Region Global Industry Analysis, Market Share,...

SYDNEY, N.S.

Work taking place at Cape Breton University could help small communities both locally and globally deal with water contamination issues.

Shine (Xu) Zhang is a CBU chemistry professor and holds the Tier II Canada Research Chair in healthy environments and communities and the industrial research chair in applied nanotechnology. He is working on a project that involves electrochemical water treatment which he believes can offer a green, efficient and cost-effective alternative.

Water pollution, water contamination is a global concern but its also a local problem for Cape Breton and Nova Scotia, Zhang said.

He said he wanted to take on water contamination as a research topic because it is such a big issue.

CBU is a local university, but CBU really wants to contribute to the community, Zhang said. The environment is a big issue. Water contamination is also a global issue, therefore, research here, if we do a good job, can not only help local communities but also help people far away from here.

We want to apply what we learn to solve some real-world problems.

His research program aims at exploiting nanotechnology and nanomaterials for environmental and health applications with a focus on water treatment, cancer diagnostics and treatment with precision nanomedicine. Zhang has published 65 journal articles.

He describes the technology hes developed as being relatively simple, with an electrode acting like a filter. One electrode removed organic material while another electrode removed heavy metals.

Water comes through the filter, dirty water becomes clean, Zhang said.

The technology, I feel is useful because, from a research standpoint, energy consumption is very low, so essentially its quite cost-effective. That is compatible, for example, with solar panel, those kinds of various sustainable power source. It can be a very automatic system, so you dont need a lot of manpower to run it.

A request for proposals for a market research consultant issued by CBU recently closed and Zhangs team is currently reviewing the proposals received. It asked for proposals to outline how the consultant would go about understanding and marketing the technology, from lab to market through the successful negotiation of a licence.

Zhang said they are now evaluating the best way to commercialize the technology.

Were looking for different industry partners so that we can do further development of specific products or applications for this to meet different needs, he said. For example, we work with environmental remediation companies, we work with landfill leachate, we work on pharmaceutical wastewater. We want to find industry partners to work on further development.

Its hoped the consultant that they hire will assist in finding those partners. A prototype has been developed.

The ideal starting industry level would be 3,000 litres a day, were about halfway there already, were at about 1,500 litres a day," said Andrew Carrier, who works closely with Zhang.

Carrier noted the technology also works in flows, so you dont need a large quantity of contaminated water to make use of it, and it doesnt take up much physical space. They want the technology to be accessible to as many people who can make use of it as possible, he added.

Its easy to put into a remote location without having to invest much capital, Carrier said.

Zhang noted the technology also doesnt generate any sort of secondary waste as a result of its water treatment.

Zhangs work has been supported by the Atlantic Canada Opportunities Agency, Innovacorp, Springboard Innovation Mobilization program, Nova Scotia Lands as well as CBU.

RELATED:

Read the rest here:
Cape Breton University researchers hope to help water woes - TheChronicleHerald.ca

DOYLESTOWN, Pa., Jan. 28, 2020 (GLOBE NEWSWIRE) -- Kannalife, Inc. (Kannalife or the Company) (KLFE), a biopharmaceutical company specializing in the research and development of cannabinoid therapeutics, announced today that it has issued a letter to its shareholders providing commentary on the Companys recent initiatives and corporate updates.

The Companys Chief Executive Officer, Dean Petkanas, commented: 2019 was a milestone year for Kannalife. Its nice to see dedicated shareholders, management, employees and trusted partners and collaborators bring a small enterprising 10-year-old startup company to the cusp of expansion and commercialization efforts in 2020. With limited resources over the past decade, we have been truly blessed as we have built an impressive track record in the cannabinoid therapeutics space. We can now share the potential of our science with investors as a publicly traded company. We hope our existing and future shareholders will join us in our excitement as Kannalife continues to execute on innovative new technologies in the biotech and pharmaceutical arena.

Highlights of the letter include:

To read the Letter to Shareholders in full, please visit: https://www.kannalife.com/wp-content/uploads/2020/01/Kannalife-Inc.-Shareholder-Letter-200128.pdf.

About KLS-13019KLS-13019 is Kannalifes leading proprietary investigational CBD-like product for the potential treatment of a range of neurodegenerative and neuropathic pain disorders, beginning with chemotherapy-induced peripheral neuropathy (CIPN). KLS-13019 has not been reviewed or approved for patient use by the U.S. Food and Drug Administration (FDA) or any other healthcare authority in the world. Its safety and efficacy have not been confirmed by FDA-approved research.

About Kannalife, Inc.Kannalife, Inc. is a biopharmaceutical company focused on the development of proprietary and patented cannabidiol (CBD) and CBD-like molecules for patients suffering from unmet medical needs of neurodegenerative disorders - including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE) a disease associated with highly repetitive impact injuries in professional and amateur sports.

The Company's family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.

For more information about Kannalife, Inc., visit http://www.kannalife.com and visit the Companys Twitter page at @Kannalife.

Forward-Looking StatementsThis press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This press release contains statements about expected future events, the companys business plan, plan of operations, the viability of the companys drug candidates, and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements, by definition, involve risks and uncertainties. The company does not sell or distribute any products that are in violation of the United States Controlled Substances Act.

CONTACT:

Public Relations:

Andrew Hard, Chief Executive Officer of CMW MediaP: 888-829-0070E: andrew.hard@cmwmedia.com

Mike Mulvihill, Senior Counsel, PadillaP: 804-334-2292E: mike.mulvihill@padillaco.com

Investor Relations: Scott Gordon, Managing Director of CORE IRP: 516-222-2560E: scottg@coreir.comwww.coreir.com

View original post here:
Kannalife, Inc. CEO Recaps 2019 Advances and Potential Ahead - Yahoo Finance

TULSA, Okla. Cancer treatment is more than surgery, radiation and chemotherapy.

Physical and occupational therapy are also important tools in a patient's fight for a normal life.

Merideth Metz used customized therapy to recover from the side effects that can occur with treatment.

When a doctor told Metz to give up after her colon cancer diagnosis, she left and went to Cancer Treatment Centers of America in Tulsa about a year and a half ago.

"No active cancer as of last September, confirmed in October, and now, I'm here for my first three month check," Metz said.

Once her chemotherapy was done, she needed physical therapy, speech therapy and occupational therapy to help with neuropathy that's common after chemo.

"Our job is to focus on the patient's wants," said Barry Calvert, an occupational therapist with CTCA. "Trying to help them stay actively participating in those as best they can throughout the course of their treatment."

Calvert came up with a creative option, like art to document her journey towards healing.

Now, Metz is looking forward to her next effort in the new year.

To learn more about Cancer Treatment Centers of America, click here.

Stay in touch with us anytime, anywhere.

Download our free app for Apple and Android and Kindle devices.

Sign up for newsletters emailed to your inbox. Select from these options: Breaking News, Severe Weather, School Closings, Daily Headlines and Daily Forecasts.

Follow us on Twitter

Like us on Facebook

Originally posted here:
Health News 2 Use: Customized therapy helps patients recover - kjrh.com

MONTROSE TWP, MI The 83-year-old man who died following a fire at a Montrose Township home is being remembered by family as kind.

Firefighters were called out around 6:50 p.m. Jan. 24, to a blaze at the Riverside Mobile Home Park located at the corner of Virginia and Joan drives.

A man inside the home died in the fire. He has been identified by family as Ellis Paul Kuykendall, 83.

Man found dead at scene of Montrose mobile home fire

Lisette McKiernan, Kuykendalls granddaughter, said he was originally from Tennessee but grew up in Las Vegas.

McKiernan took care of Kuykendall for the last decade prior to him moving in with her son Matthew Price several months ago.

Theyd lived in the mobile home park for approximately three weeks before the fire.

Kuykendall was a U.S. Air Force veteran, serving two years of active duty.

He was just a very witty man, said McKiernan. He had a good sense of humor. He was just a very kind individual."

Kuykendall enjoyed playing word searches and rummy. McKiernan kidded that his nurses had to learn the game in order to get in some games.

Hed been diagnosed with neuropathy in his legs that left him wheelchair-bound, McKiernan said.

No other injuries took place in the fire, but McKiernan said her son and two grandchildren -- a 4-year-old boy and a 6-year-old girl -- lost their home.

Were just pretty much devastated right now, she said.

Community members have reached out to Price with donations.

Thank you to the community for reaching out and all their support, said McKiernan. Matthew appreciates everything the community has provided for them.

A GoFundMe page has been set up to help the family transport Kuykendall back to Las Vegas and help Price get back on his feet.

The cause of the fire remains under investigation.

See the article here:
Veteran who died after Montrose-area fire remembered as witty, kind - MLive.com

Abstract / Synopsis:

Gene therapy for Leber's hereditary optic neuropathy appears highly promising for increasing the best-corrected visual acuity in this patient population.

This article was reviewed by Jiajia Yuan, PhD

Gene therapy for Lebers hereditary optic neuropathy (LHON) seems to be the first promising treatment for the disease.

LHON, a maternally inherited disease, causes optic nerve atrophy that in most cases results in simultaneous or sequential bilateral visual loss. Disease onset typically happens in patients between 14 to 21 years of age.

The most frequently occurring offending mutation is ND4 that appears in about 90% of Chinese patients and in about 50% to 60% of U.S. patients, according to Jiajia Yuan, PhD, Tongjl Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

No treatment is currently available for this disease.

Related:Gene therapy offering hope for retinal, corneal patients

LHON treatmentDr. Yuan and colleagues initially treated nine patients with LHON with gene therapy in 2011. With this first attempt, she reported seven of the nine patients had a significant improvement of 0.3 logarithm of the minimum angle of resolution (logMAR) VA at 36 months in the best-corrected visual acuity (BCVA).

We saw a durable response in six of these patients out to 75 to 90 months after treatment, she said. In addition, a bilateral improvement was achieved, as also was observed by other groups investigating gene therapy.

Gene therapy trialThese promising results prompted a second multicenter gene therapy trial that began in 2017 that include 149 Chinese patients and 10 Argentinian patients.

According to Dr. Yuan, the patients, who ranged in age from 7 to 45 years, received a fixed dose of 1 x 1010 mg/eye for all patients, regardless of age, Dr. Yuan explained.

Related: Research targets precision data for gene, cell therapy

Promising resultsThe treatment was found to be well tolerated and no severe adverse effects occurred, she said.

Keratitis developed in one eye at one month and anterior inflammation in one eye at three months that were both considered to be unrelated to the treatment.

Ocular hypertension was the most common adverse event that developed in 27.04% of eyes that decreased slowly over time after cessation of the steroid.

A significant improvement in the BCVA occurred in 63.21% (67 of 106 patients) at 12 months. The rest of the patients had not reached the 12-month time point at the time of this report. Similar to the initial study, the patients showed bilateral improvement.

This is a real-world study, in that there was no specific patient selection, Dr. Yuan explained. The patients ages spanned a wide range as did the time of disease onset and the pretreatment BCVA.

An evaluation of only the Argentinian patients showed that all had improvement in the BCVA.

These patients fared better overall than the other patients in the group, with the average improvement in the treated eye was 0.6 logMAR and the average improvement in the untreated eye was 0.9 logMAR, Dr. Yuan pointed out.

Related: Gene therapy for LHON: Deciphering phase III data

Importantly, this improvement in the BCVA is highly relevant for the ability of patients to function well during everyday tasks.

And the researchers saw results with the patients that were treated.

Dr. Yuan related that three months after treatment, a patient was able to cook and watch sporting events on the computer.

Dr. Yuan noted that gene therapy is a promising approach for patients with LHON.

Nine patients were treated in 2011 to 2012 and we continue to follow them, she concluded. This is the longest term data from human gene therapy to date.

Related: Gene therapy focus of Schepens lectures at AAO 2019

ConclusionsAccording to Dr. Yuan, nearly two-third of 106 patients who reached the 12-month follow-up point achieved a clinically significant improvement in the BCVA.

Importantly, no serious adverse events occurred in the real-world studies, she said. We are very excited about the potential impact of gene therapy on this disease.

Read more by Lynda Charters

Jiajia Yuan, PhDE: [emailprotected]This article is based on Dr. Yuan's presentation at the American Academy of Ophthalmology's 2019 annual meeting. Dr. Yuan has no financial interest in any aspect of this report.

Read the rest here:
Gene therapy zeroes in as LHON treatment - Ophthalmology Times